Immune checkpoint blockade has introduced exciting possibilities to the field of targeted cancer therapy to inhibit tumor growth, with exploitation of programmed death-ligand 1 (PD-L1) showing great therapeutic promise (Pardoll, 2012). This evidence concerns the gene CD274 and neoplasm.